Menu

Recent Interviews

Heye Daun, President and CEO, Osino Resources Corp.

Heye Daun
President and CEO | Osino Resources Corp.
Suite 810 – 789 West Pender Street, V6C 1H2 Vancouver (CAN)

jbecker@osinoresources.com

Interview Osino Resources: "The market has not yet realized how fast we are advancing Twin Hills."


Bradley Rourke, President, CEO and Director, Scottie Resources Corp.

Bradley Rourke
President, CEO and Director | Scottie Resources Corp.
905 - 1111 West Hastings Street, V6E 2J3 Vancouver (CAN)

info@scottieresources.com

+1 250-877-9902

Interview Scottie Resources: Exciting Story in the Golden Triangle


Jerre Foo, Corporate Development Executive, Silkroad Nickel

Jerre Foo
Corporate Development Executive | Silkroad Nickel
50 Armenian Street #03-04, 179938 Singapore (SGP)

enquiries@silkroadnickel.com

+65 6327 8971

Silkroad Nickel: 'The course is set for dynamic profit growth.'


13. January 2020 | 11:33 CET

Agrios Global Holdings LTD - still on track

  • Cannabis
Photo credits: pixabay.com

Agrios Global Holdings is an agricultural technology company with a focus on the latest innovations in indoor growing and data analytics. The company's technology can be used for all types of indoor cultivation. The company rents and manages real estate and equipment for environmentally sustainable indoor agriculture. The company offers leasing and cultivation services in the field of data-controlled aeroponic cultivation systems for cannabis producers. Furthermore, the company provides consulting services to support the cannabis sector.

time to read: 1 minutes by Mario Hose


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


Update to the cannabis market

Agrios Global Holdings (Agrios) is still a young company with high growth potential, according to the experts at GBC Research. The company currently owns a state-of-the-art production facility in Washington State, which is leased to a licensed cannabis producer and processor. Agrios also leases data-driven aeroponics cultivation systems and cultivation services to cannabis producers. The company's technology can also be used for any type of indoor cultivation.

The US Indoor Aeroponics market is expected to reach USD 40 billion annually by 2022. In addition, the US cannabis market is estimated to reach USD 75 billion annually by 2030. The market in the state of Washington was still around USD 1.37 billion in 2017 and is expected to grow to USD 2.28 billion by 2020.

Sales increase compared to the previous year

Agrios Holdings recorded an increase in its product and service revenues and a slight increase in rental / IP revenues in the second quarter of fiscal 2019/2020, which ends March 31, 2020, representing a total increase of 8.54% over the previous quarter to USD 1.093 million compared to USD 1.007 million in the previous quarter.

Revenues must increase significantly in Q3 and Q4 of the current 2019/2020 financial year in order to meet GBC Research's overall year guidance.

Still on track

For the current financial year 2019/2020e, analysts at GBC had previously forecast a small negative after-tax result of USD 1.5 million. They had expected the company to report negative cash flows in the first two quarters of the current 2019/2020 financial year. Only from the third quarter onwards should the operating cash flow turn positive. The company is well on the way to meeting these expectations.

In the second quarter of 2019, EBITDA was USD -0.524 million, a significant improvement on the previous year's USD -1.789 million. EBIT also showed significant improvements and amounted to USD -0.615 million, which is significantly above the previous year's level of USD -1.843 million. The experts at GBC have raised their price target from CAD 1.38 to CAD 1.64 and confirmed the BUY rating.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

04. March 2021 | 09:16 CET | by Stefan Feulner

NanoRepro, EXMceuticals, Deutsche Telekom - The profiteers of the new world!

  • Cannabis

The world has changed since last year. The goal is to fight and contain the virus, which has destroyed our everyday life. In addition to the vaccine manufacturers such as BioNTech, AstraZeneca or Moderna, there are more and more new winners emerging from nowhere to become new stock market stars. Currently, the dominant topic, apart from the vaccination programs that are still hardly taking place in Germany, is the "national testing strategy." At the very least, this should enable a more regular and open life. Be there!

Read

07. December 2020 | 10:01 CET | by André Will-Laudien

EXMceuticals, Aurora, Xphyto Therapeutics - Cannabis 2.0 and Psilocybin!

  • Cannabis

The North American Cannabis Index has brought itself back to life in October! The index lost 80% since the beginning of 2019, but it's going up again with the survivors of the industry. Overall, the capitalization of the sector has decreased by 85%, with the election of Joe Biden, the second buying wave of purchases is underway. If hemp production was the initial focus, it is now the applications, the achieved market access and new active ingredient combinations. In the slipstream of the therapeutic plant customer, another topic came to the fore that has caused investors' hearts to stutter in recent weeks: the psychedelic drugs in the form of psilocybin. Psilocybin has been used as an entheogen and hallucinogenic drug since prehistoric times. Now the medical applications are being investigated. The trend is already running at full speed, the Canadian brokerage house Canaccord estimates the market volume of all indications that are suitable for treatment with active psychedelic ingredients to be USD 100 billion.

Read

15. July 2020 | 12:23 CET | by Mario Hose

BioNTech, EXMceuticals, XPhyto - Covid-19 and legalizations offer potential

  • Cannabis

In recent months, the society around the globe has been going through a process of change of deceleration and standstill. Priorities have been redefined and implemented at record speeds in many places. Covid-19 serves as a catalyst for change for many people. The reasons can be different. The development of corona vaccines and antibody tests will make a lot of money in the future and the legalization of cannabis in the USA on a federal level has the potential to create a renaissance.

Read